Sutherland Health Group PlcSutherland Health Group Plc
About Us Investor Products and Services News Jobs Contact Us Home
Sexual Health Group Plc

Company News

18 NOVEMBER 2004

SEXUAL HEALTH GROUP PLC

THE GOVERNMENT WHITE PAPER ON SEXUAL HEALTH AND SEXUAL HEALTH GROUP PLC – A NATIONAL SUPPLIER OF SEXUAL HEALTH PRODUCTS

The Board of Sexual Health Group (“SHG” or “the Company”), a national supplier of sexual health products to customers including the National Health Service (“NHS”) and the British Armed Forces, notes that The Government has, this week, published its long awaited White Paper on Health, which addresses the subject of sexual health.

The key points for SHG are:

  1. Introduction of a new National Screening Programme for Chlamydia;
  2. Targeting 16-30 year olds (the ‘Condomania’ condom brand target market);
  3. A new campaign by the Government to promote the use of condoms to avoid the risk of Sexually Transmitted Infections (“STIs”) and unplanned pregnancies;
  4. Government increasing capital expenditure on modernising sexual health services and its provision;
  5. Increased and more efficient Sexually Transmitted Infection screening programmes; and
  6. Contraceptive review in 2005 with investment from central funds in addition to local funds to meet gaps in local services.

All these points impact positively on the Company’s plans, and further strengthens its position as a potential key supplier in this market.

The Company is currently raising funds by way of an Offer for Subscription and will seek to have it shares traded on the OFEX Market.

George Sutherland, Chief Executive of Sexual Health Group, said “We are encouraged by the proposed strategies to be implemented by the Government. Educating the public about the benefits of condom use and how to avoid the risk of STIs, coupled with PCT’s working to target 16-30 year olds fits with our own marketing programme.

“We are very excited about our forthcoming flotation and welcome the improvements in provision of services for screening of STIs. With particular emphasis on Chlamydia, this confirms our decision to enter this market”.

 << return to Company News  

Sutherland Health Group Plc logo
disclaimer | privacy | terms CE 0120 quality mark
site by pedalo limited